We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NIH Should Consider Drug Affordability When Licensing, GAO Says
NIH Should Consider Drug Affordability When Licensing, GAO Says
The National Institutes of Health (NIH) should disclose more information about the licensing of its intellectual property and the impact on the affordability of drug products, the Government Accountability Office said in a new report to Congress.